[Molecular target therapy for colonic neoplasms].

Oki, Eiji; Ota, Mitsuhiko; Honbo, Takuya; Egashira, Akinori; Tokunaga, Eriko; Sadanaga, Noriaki; Morita, Masaru; Kakeji, Yoshihiro; Maehara, Yoshihiko

Oki, Eiji; Ota, Mitsuhiko; Honbo, Takuya; Egashira, Akinori; Tokunaga, Eriko; Sadanaga, Noriaki; Morita, Masaru; Kakeji, Yoshihiro; Maehara, Yoshihiko.

Nihon Naika Gakkai Zasshi ; 96(2): 289-94, 2007 Feb 10.

Article in Ja | MEDLINE | ID: mdl-17370595

Subject(s)

Angiogenesis Inhibitors/therapeutic use; Antibodies, Monoclonal/therapeutic use; Antineoplastic Agents/therapeutic use; Colonic Neoplasms/drug therapy; Colonic Neoplasms/etiology; Angiogenesis Inhibitors/adverse effects; Antibodies, Monoclonal/adverse effects; Antibodies, Monoclonal, Humanized; Antineoplastic Agents/adverse effects; Bevacizumab; Cetuximab; Drug Design; Drug Therapy, Combination; ErbB Receptors/immunology; Humans; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A/immunology

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Colonic Neoplasms / Angiogenesis Inhibitors / Antibodies, Monoclonal / Antineoplastic Agents Type of study: Clinical_trials / Prognostic_studies Limits: Humans Language: Ja Journal: Nihon Naika Gakkai Zasshi Year: 2007 Document type: Article Country of publication: Japan

Search on Google

Add to My VHL

XML

PubMed Links